| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
121,863 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$226,133 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2020-11-17 |
4 |
AS |
$30.00 |
$109,980 |
D/D |
(3,666) |
1,473 |
|
-29% |
|
| Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2020-11-17 |
4 |
OE |
$5.88 |
$11,760 |
D/D |
2,000 |
5,139 |
|
- |
|
| Hofmeister Robert |
Chief Scientific Officer |
• – – |
2020-11-12 |
4 |
AS |
$25.10 |
$502,000 |
D/D |
(20,000) |
38,850 |
|
-18% |
|
| Hofmeister Robert |
Chief Scientific Officer |
• – – |
2020-11-12 |
4 |
OE |
$0.74 |
$14,800 |
D/D |
20,000 |
48,852 |
|
- |
|
| Hofmeister Robert |
Chief Science Officer |
• – – |
2020-10-29 |
4 |
AS |
$19.10 |
$382,000 |
D/D |
(20,000) |
38,850 |
|
43% |
|
| Hofmeister Robert |
Chief Science Officer |
• – – |
2020-10-29 |
4 |
OE |
$0.74 |
$14,800 |
D/D |
20,000 |
58,850 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2020-08-31 |
4 |
A |
$10.10 |
$11,290 |
D/D |
1,118 |
3,043 |
|
- |
|
| Menzel Garry E |
President and CEO |
• • – |
2020-08-31 |
4 |
A |
$10.10 |
$11,431 |
D/D |
1,132 |
3,399 |
|
- |
|
| Gibson Neil W |
Director |
– • – |
2020-03-20 |
4 |
S |
$7.94 |
$5,145 |
I/I |
(648) |
0 |
|
-148% |
|
| Gibson Neil W |
Director |
– • – |
2020-03-19 |
4 |
S |
$7.41 |
$23,267 |
I/I |
(3,140) |
648 |
|
-149% |
|
| Gibson Neil W |
Director |
– • – |
2020-03-18 |
4 |
S |
$6.83 |
$21,310 |
I/I |
(3,120) |
3,788 |
|
-165% |
|
| Gibson Neil W |
Director |
– • – |
2020-03-17 |
4 |
S |
$6.49 |
$19,528 |
I/I |
(3,009) |
6,908 |
|
-156% |
|
| Gibson Neil W |
Director |
– • – |
2020-03-16 |
4 |
S |
$6.60 |
$117,043 |
I/I |
(17,723) |
9,917 |
|
-101% |
|
| Gibson Neil W |
Director |
– • – |
2020-03-13 |
4 |
S |
$6.52 |
$338,894 |
I/I |
(52,000) |
27,640 |
|
-101% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2020-02-28 |
4 |
A |
$10.10 |
$10,928 |
D/D |
1,082 |
1,925 |
|
- |
|
| Menzel Garry E |
President & CEO |
• • – |
2020-02-28 |
4 |
A |
$10.10 |
$12,999 |
D/D |
1,287 |
2,267 |
|
- |
|
| Somaiya Mayur Ian |
Chief Financial Officer |
• – – |
2020-02-28 |
4 |
A |
$10.10 |
$14,877 |
D/D |
1,473 |
3,139 |
|
- |
|
| Baeuerle Patrick |
Director |
– • – |
2019-12-23 |
4 |
AS |
$15.44 |
$1,310,964 |
I/I |
(84,907) |
350,786 |
|
- |
|
| Baeuerle Patrick |
Director |
– • – |
2019-12-20 |
4 |
AS |
$15.16 |
$485,454 |
I/I |
(32,022) |
435,693 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-12-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(600,000) |
161,024 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-12-19 |
4 |
S |
$16.47 |
$691,222 |
I/I |
(41,965) |
155,986 |
|
- |
|
| F2 Capital I 2019, Llc |
10% Owner |
– – • |
2019-12-18 |
4 |
S |
$17.01 |
$49,164 |
I/I |
(2,891) |
191,309 |
|
- |
|
| F2 - Tpo Investments Llc |
10% Owner |
– – • |
2019-12-11 |
4 |
S |
$17.65 |
$136,683 |
I/I |
(7,743) |
1,299,876 |
|
- |
|
| F2 - Tpo Investments Llc |
10% Owner |
– – • |
2019-12-10 |
4 |
S |
$17.62 |
$1,001,526 |
I/I |
(56,830) |
1,304,029 |
|
- |
|
| F2 - Tpo Investments Llc |
10% Owner |
– – • |
2019-12-09 |
4 |
S |
$17.65 |
$2,470,960 |
I/I |
(139,989) |
1,334,504 |
|
- |
|
132 Records found
|
|
Page 4 of 6 |
|
|
